CHINA RESOURCES BOYA BIO-PHARMACEUTICAL GROUP CO.,LTD China Resources Boya Bio-pharmaceutical Group Co.,Ltd Share Price
Equities
300294
CNE100001FF1
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 31.28 CNY | -0.29% |
|
-1.14% | -7.13% |
| Sales 2024 * | 1.91B 263M 21.1B | Sales 2025 * | 2.08B 287M 22.95B | Capitalization | 15.77B 2.18B 174B |
|---|---|---|---|---|---|
| Net income 2024 * | 549M 75.77M 6.07B | Net income 2025 * | 603M 83.22M 6.66B | EV / Sales 2024 * | 8.26 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 7.59 x |
| P/E ratio 2024 * |
28.8
x | P/E ratio 2025 * |
26.2
x | Employees | 1,444 |
| Yield 2024 * |
0.99% | Yield 2025 * |
1.12% | Free-Float | 16.25% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.29% | ||
| 1 week | -1.14% | ||
| Current month | +8.91% | ||
| 1 month | +14.16% | ||
| 3 months | +9.72% | ||
| 6 months | +7.82% | ||
| Current year | -7.13% |
1 week
30.64
32.29
1 month
27.6532.29
Current year
22.9134.09
1 year
22.9138.98
3 years
22.9156.80
5 years
22.0858.15
10 years
8.8858.15
| Managers | Title | Age | Since |
|---|---|---|---|
Xiao Ming Liang
CEO | Chief Executive Officer | 57 | 05/11/93 |
Hua Cheng Liang
DFI | Director of Finance/CFO | 42 | 31/08/21 |
Zhen Rao
BRD | Director/Board Member | 56 | 05/11/93 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Wei Dong Zhang
BRD | Director/Board Member | 61 | 02/02/21 |
Xiao Ming Liang
CEO | Chief Executive Officer | 57 | 05/11/93 |
Zhen Rao
BRD | Director/Board Member | 56 | 05/11/93 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 31.28 | -0.29% | 4,754,105 |
| 25/04/24 | 31.37 | -1.07% | 5,096,226 |
| 24/04/24 | 31.71 | +1.73% | 6,388,069 |
| 23/04/24 | 31.17 | -1.08% | 3,906,015 |
| 22/04/24 | 31.51 | -0.41% | 4,949,545 |
End-of-day quote Shenzhen S.E., April 25, 2024
More quotes
China Resources Boya Bio-pharmaceutical Group Co Ltd, formerly Boya Bio-pharmaceutical Group Co Ltd, is a China-based company principally engaged in the research, development, production and distribution of blood products. The Company's main products include human albumin, freeze-drying intravenous injection human immune globulin, human immune globulin, hepatitis B human immune globulin, hydrophobia human immune globulin, human fibrinogen, metformin hydrochloride, calcium dobesilate capsules, glimepiride and pioglitazone hydrochloride dispersible tablets, among others. The Company's blood products are mainly used in the treatment of tumor, liver diseases and diabetes, among others. The Company also provides diabetic pharmaceuticals and biochemical pharmaceuticals. The Company distributes its products mainly in domestic market.
Sector
Pharmaceuticals
Calendar
28/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
31.28
CNY
Average target price
34.45
CNY
Spread / Average Target
+10.12%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -7.13% | 2.18B | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| -9.14% | 11.95B | |
| +5.24% | 8.71B | |
| -8.42% | 8.12B |
- Stock Market
- Equities
- 300294 Stock
